323 related articles for article (PubMed ID: 37211260)
1. Efficacy of meropenem extended infusion vs intermittent bolus monotherapy and in combination with colistin against Pseudomonas aeruginosa biofilm.
Benavent E; Ulldemolins M; El Haj C; Rigo-Bonnin R; Yu H; Wang L; Wickremasinghe H; Ariza J; Murillo O
Int J Antimicrob Agents; 2023 Aug; 62(2):106856. PubMed ID: 37211260
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
[TBL] [Abstract][Full Text] [Related]
3. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model.
Lora-Tamayo J; Murillo O; Bergen PJ; Nation RL; Poudyal A; Luo X; Yu HY; Ariza J; Li J
J Antimicrob Chemother; 2014 Sep; 69(9):2434-42. PubMed ID: 24833752
[TBL] [Abstract][Full Text] [Related]
4. The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection.
Wang Y; Li C; Wang J; Bai N; Zhang H; Chi Y; Cai Y
Microbiol Spectr; 2022 Oct; 10(5):e0146822. PubMed ID: 36102678
[TBL] [Abstract][Full Text] [Related]
5. In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm.
Gómez-Junyent J; Murillo O; Yu HH; Azad MAK; Wickremasinghe H; Rigo-Bonnin R; Benavent E; Ariza J; Li J
Int J Antimicrob Agents; 2021 Feb; 57(2):106246. PubMed ID: 33253904
[TBL] [Abstract][Full Text] [Related]
6. Comparative Efficacy of Continuous Ceftazidime Infusion vs. Intermittent Bolus against In Vitro Ceftazidime-Susceptible and -Resistant
El Haj C; Agustí E; Benavent E; Soldevila-Boixader L; Rigo-Bonnin R; Tubau F; Torrejón B; Esteban J; Murillo O
Antibiotics (Basel); 2024 Apr; 13(4):. PubMed ID: 38667020
[No Abstract] [Full Text] [Related]
7. Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm Model.
Bilal H; Bergen PJ; Tait JR; Wallis SC; Peleg AY; Roberts JA; Oliver A; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32366710
[TBL] [Abstract][Full Text] [Related]
8. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones.
Montero MM; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Segura C; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
J Glob Antimicrob Resist; 2019 Sep; 18():37-44. PubMed ID: 31154007
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model.
Bilal H; Bergen PJ; Kim TH; Chung SE; Peleg AY; Oliver A; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427301
[TBL] [Abstract][Full Text] [Related]
10. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection.
Hengzhuang W; Wu H; Ciofu O; Song Z; Høiby N
Antimicrob Agents Chemother; 2012 May; 56(5):2683-90. PubMed ID: 22354300
[TBL] [Abstract][Full Text] [Related]
11. Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm.
Badawy MSEM; Elkhatib WF; Shebl RI
Ann Clin Microbiol Antimicrob; 2023 Jul; 22(1):53. PubMed ID: 37394468
[TBL] [Abstract][Full Text] [Related]
12. Bacteriophage-antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa: In vitro synergy testing.
Holger DJ; Lev KL; Kebriaei R; Morrisette T; Shah R; Alexander J; Lehman SM; Rybak MJ
J Appl Microbiol; 2022 Sep; 133(3):1636-1649. PubMed ID: 35652690
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates.
Montero MM; Domene-Ochoa S; López-Causapé C; López-Montesinos I; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Ferrer Alapont L; Grau S; Oliver A; Horcajada JP
Microbiol Spectr; 2022 Jun; 10(3):e0089222. PubMed ID: 35695526
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an
Montero M; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Angulo-Brunet A; Padilla E; Prim N; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041712
[TBL] [Abstract][Full Text] [Related]
15. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Sumitani Y; Kobayashi Y
Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
[TBL] [Abstract][Full Text] [Related]
16. [In vitro activity of ceftazidime-avibactam combined with colistin against extensively drug-resistant Pseudomonas aeruginosa].
Mei Q; Geng S; Fang X; He Y; Liu L; Xu M; Zhu C; Pan A
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Oct; 31(10):1212-1218. PubMed ID: 31771717
[TBL] [Abstract][Full Text] [Related]
17. Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.
Mohamed AF; Kristoffersson AN; Karvanen M; Nielsen EI; Cars O; Friberg LE
J Antimicrob Chemother; 2016 May; 71(5):1279-90. PubMed ID: 26850719
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
[TBL] [Abstract][Full Text] [Related]
19. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
Albiero J; Mazucheli J; Barros JPDR; Szczerepa MMDA; Nishiyama SAB; Carrara-Marroni FE; Sy S; Fidler M; Sy SKB; Tognim MCB
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]